UCL AI discovers combo therapy that may extend survival for rectal cancer patients

Artificial intelligence researchers at University College London (UCL) have identified a promising combination of existing cancer therapies that could extend survival for patients with locally advanced rectal cancer. By analysing large datasets of clinical outcomes, the AI model highlighted a synergistic effect when a standard chemoradiation regimen is paired with a targeted immunotherapy agent, suggesting that the combined approach may more effectively eradicate tumour cells while preserving healthy tissue.

The study, conducted by a multidisciplinary team of oncologists, data scientists, and bioinformaticians, used machine‑learning algorithms to sift through thousands of treatment records and imaging studies. The AI pinpointed specific biomarkers that predict which patients are most likely to benefit from the dual‑modality strategy, offering a potential pathway toward more personalized care. Early laboratory and retrospective analyses indicate that the combination could reduce tumour recurrence rates and improve overall survival compared with conventional treatment alone.

If validated in prospective clinical trials, this finding could reshape standard care protocols for locally advanced rectal cancer. UCL researchers are now preparing to collaborate with oncology centres to initiate phase‑II studies that will assess safety, efficacy, and optimal dosing schedules for the combined therapy. The prospect of a more effective, data‑driven treatment option brings renewed hope for patients and underscores the growing role of artificial intelligence in oncology research.